SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement…

CATALYST PHARMACEUTICALS, INC. · 8-K filed May 7, 2026 at 08:45 ET

At the news

BULLISHIMPACT 9/10

8-K filed May 7, 2026 at 08:45 ET

Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement to be acquired by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The price reflects a 28% premium to the 30-day volume-weighted average price. Separately, Catalyst resolved all remaining FIRDAPSE patent litigation, with Hetero agreeing not to launch a generic version before January 2035, strengthening the IP outlook for the flagship product.

  • Acquisition price: $31.50 per share in cash
  • Total equity value: ~$4.1 billion
  • Premium: 28% to unaffected 30-day VWAP as of April 22, 2026
  • Expected closing: Q3 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access